KannaLife Sciences has partnered with Advanced Neural Dynamics and IteraMed for the discovery of new neuroprotectants.
As part of the agreement, KannaLife will fund a new drug discovery project related to a laboratory validated phytochemical.
The founding science is based on the licensed technology of Dr. A. J. Hampson at the laboratory of cellular and molecular regulation within the National Institutes of Mental Health, US.
Dr. Hampson's research has shown that this phytochemical is neuroprotective in cortical neuronal cultures exposed to toxic levels of glutamate or oxidative stress, according to KannaLife.
KannaLife CEO Dean Petkanas said the opportunity to begin the company's research and development program at the Pennsylvania Biotechnology Center, would not be possible without the support and financial backing of our investors, Medical Marijuana (MJNA) and CannaVEST.
"Having this shared vision and support from MJNA and CannaVest is crucial to the long range research and development efforts planned between KannaLife, IteraMed and Advanced Neural Dynamics," Petkanas added.
IteraMed and Advanced Neural Dynamics are located at the 112,000 ft2 Pennsylvania Biotechnology Center, which is a biotechnology incubator in Doylestown.
